Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Sandborn WJ, Rebuck R, Wang Y, Zou B, et al. Clin Gastroenterol Hepatol 2022;20:578-590.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sandborn WJ, Rebuck R, Wang Y, Zou B, et al. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol 2022;20:578-590.
PMID: 33618023